APOL1 Targeted Therapies: Who to Test and Which Disease to Treat?

14 Apr 2024 9:00am 10:30am
Hall C2
FernandaSales Luiz Vianna Chairperson Universidade Federal do Rio Grande do SulBrazil
OpeyemiOlabisi Chairperson Duke University School of MedicineUnited States
Fatiu AbiolaArogundade Chairperson Obafemi Awolowo University Teaching Hospitals Complex/ National Postgraduate Medical College of Nigeria Nigeria

Session Description:
Genetic variants in APOL1 are a major contributor to the increased risk of kidney disease in people of recent African ancestry. In this session, recent insight into the contribution of the APOL1 risk genotype to different renal phenotypes will be highlighted, as well as the difficulty in determining when to when to screen and where to apply APOL1 genotype data in clinical practice. In addition, a long-lasting study showing the promise of a small-molecule inhibitor of APOL1 channel function as potential treatment will be discussed.
Learning Objectives:
Understand recent insight into contribution of APOL1 genetic risk variants to chronic kidney disease, and the potential of targeted treatments. Review the arguments (including ethical) for and against genetic testing of APOL1.

Time Session
Ethical Aspects of Race-based Genetic Testing
AnaIltis Speaker iltisas@wfu.eduWake Forest UniversityUnited States
Contribution of ApoL1 Risk Genotype to HIVAN
SaraladeviNaicker Speaker Saraladevi.Naicker@wits.ac.zaUniversity of the Witwatersrand South Africa
Contribution of APOL1 Risk Alleles to Kidney Disease in West Africa
DwomoaAdu Speaker dwoms@blueyonder.co.ukUniversity of Ghana Medical SchoolGhana
Targeting ApoL1: A 12-Year Journey from Genetic Discovery to Phase 2 Trials
OgoEgbuna Speaker ogo_egbuna@vrtx.comVertex Pharmaceuticals IncUnited States
Q and A